P/E ratio for 10x Genomics (TXG)
P/E ratio as of July 2025 (TTM): -10.8
According to 10x Genomics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -10.7692. At the end of 2024 the company had a P/E ratio of -9.45.
P/E ratio history for 10x Genomics from 2019 to 2025
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2024 | -9.45 | -63.37% |
| 2023 | -25.8 | 4.03% |
| 2022 | -24.8 | -91.35% |
| 2021 | -286 | 941.86% |
| 2020 | -27.5 | -79.8% |
| 2019 | -136 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Novocure
NVCR | -7.53 | -30.05% | Jersey |
 Novavax NVAX | 2.31 | -121.41% | 🇺🇸 USA |
 Organovo ONVO | -0.1771 | -98.36% | 🇺🇸 USA |
 Orchard Therapeutics
ORTX | -2.69 | -74.99% | 🇬🇧 UK |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.